<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">IDARUBICIN</span><br/>(i-da-a-roo'bi-cin)<br/><span class="topboxtradename">Idamycin, </span><span class="topboxtradename">Idamycin PFS<br/></span><b>Classifications:</b> <span class="classification">antineoplastic, antibiotic</span><br/><b>Prototype: </b>Doxorubicin<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg, 10 mg, 20 mg vials; 1 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Cytotoxic anthracycline antibiotic and derivative of daunorubicin. Potency of idarubicin is greater than that of daunorubicin
         or doxorubicin. It may be less cardiotoxic than other anthracyclines. Idarubicin exhibits inhibitory effects on DNA and RNA
         polymerase and, therefore, on nucleic acid synthesis. Intensive maintenance with idarubicin is not recommended due to its
         considerable toxicity, including deaths while patient was in remission of acute myelogenous leukemia (AML).
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Idarubicin exhibits inhibitory effects on DNA and RNA polymerase and, therefore, on nucleic acid synthesis.</p>
<h1><a name="uses">Uses</a></h1>
<p>In combination with other antineoplastic drugs for treatment of AML.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Breast cancer, other solid tumors.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Myelosuppression, hypersensitivity to idarubicin or doxorubicin, pregnancy (category D), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Impaired renal or hepatic function; patients who have received irradiation or radiotherapy to areas surrounding heart. Safety
         and efficacy in children not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Acute Myelogenous Leukemia (AML)</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 812 mg/m<sup>2</sup> daily for 3 d injected slowly over 1015 min<br/><br/><span class="indicationtitle">Acute Nonlymphocytic Leukemia, Acute Lymphocytic Leukemia</span><br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> 1012 mg/m<sup>2</sup>/d for 3 d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>IV administration to infants, children: Verify correct IV concentration and rate of infusion with physician.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span>  Reconstitute 5- and 10-mg vials with 5 and 10 mL, respectively, of nonbacteriostatic NS to yield 1 mg/mL. Vials are under negative pressure, therefore, carefully insert needle into vial to reconstitute. Wash skin accidentally exposed with soap and water. 
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> IV Infusion:</span>  Give slowly over 1015 min into tubing of free flowing IV of NS or D5W.  
               </p>
<ul>
<li>If extravasation is suspected, immediately stop infusion, elevate the arm, and apply ice pack for ½ h then q.i.d. for ½ h
                     <small>x</small> 3 d.
                  </li>
</ul>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span> <b>Acyclovir,</b> <span class="classification">alkaline solutions</span> (i.e., <b>sodium bicarbonate</b>), <b>ampicillin/sulbactam,</b> <b>cefazolin,</b> <b>ceftazidime,</b> <b>clindamycin,</b> <b>dexamethasone,</b> <b>etoposide,</b> <b>furosemide,</b> <b>gentamicin,</b> <b>heparin,</b> <b>hydrocortisone,</b> <b>imipenem/cilastatin,</b> <b>meperidine,</b> <b>methotrexate,</b> <b>mezlocillin,</b> <b>sargramostim,</b> <b>sodium bicarbonate,</b> <b>vancomycin,</b> <b>vincristine.</b> <span class="incompattype">Y-site:</span> Same as above. 
               </p>
</td>
</tr>
</table>
<ul>
<li>Store reconstituted solutions up to 7 d refrigerated at 2°8° C (36°46° F) and 72 h at room
            temperature 15°30° C (59°86° F).
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CV:</span> CHF, atrial fibrillation, chest pain, <span class="speceff-life">MI</span>. <span class="typehead">GI:</span> <span class="speceff-common">Nausea, vomiting, diarrhea, abdominal pain,</span> mucositis. <span class="typehead">Hematologic:</span> <span class="speceff-both">Anemia, leukopenia,</span> thrombocytopenia. <span class="typehead">Other:</span> Nephrotoxicity, hepatotoxicity, <span class="speceff-common">alopecia,</span> rash. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">immunosuppressants</span> cause additive bone marrow suppression; <span class="classification">anticoagulants</span>, <span class="classification">nsaids</span>, <span class="classification">salicylates</span>, <b>aspirin,</b> <span class="classification">thrombolytic agents</span> increase risk of bleeding; idarubicin may blunt the effects of <b>filgrastim,</b> <b>sargramostim.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead"> Onset:</span>  Median time to remission 28 d. <span class="typehead">Peak:</span> Serum level 4 h. <span class="typehead">Duration:</span> Serum levels 120 h. <span class="typehead">Distribution:</span> Concentrates in nucleated blood and bone marrow cells. <span class="typehead">Metabolism:</span> Metabolized in liver to idarubicinol, which may be as active as idarubicin. <span class="typehead">Elimination:</span> 16% excreted in urine; 17% excreted in bile. <span class="typehead">Half-Life:</span> Idarubicin 1545 h, idarubicinol 45 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor infusion site closely, as extravasation can cause severe local tissue necrosis. Notify physician if pain, erythema,
            or edema develops at insertion site.
         </li>
<li>Lab tests: Monitor hepatic and renal function, CBC with differential and coagulation studies periodically.</li>
<li>Monitor cardiac status closely, especially in older adult patients or those with preexisting cardiac disease.</li>
<li>Monitor hematologic status carefully; during the period of myelosuppression, patients are at high risk for bleeding and infection.</li>
<li>Monitor for development of hyperuricemia secondary to lysis of leukemic cells.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn all potential adverse reactions to idarubicin.</li>
<li>Anticipate possible hair loss.</li>
<li>Discuss interventions to minimize nausea, vomiting, diarrhea, and stomatitis with health care providers.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>